1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

  • September 2015
  • 43 pages
  • CBR Pharma Insights
Report ID: 3326310

Summary

Table of Contents

Search Inside

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

Summary

GBI Research’s latest report, "Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses.

Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. Gene therapies only account for a marginal market share and many efficacy and safety concerns remain unaddressed. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development.

This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.

Scope

Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success -

- Why do gene therapies still occupy only a minimal market share in their respective indications?
- What can be learned from the gene therapies that have already reached the market?

A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies -

- What are the relative advantages and disadvantages of each vector type and which hold the most promise?
- What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?

The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene -

- In which therapy areas is there the highest level of R&D activity for gene therapies?
- At which stage of development does the majority of pipeline gene therapies reside?
- What is the proportion of the pipeline occupied by each intervention and vector type overall?

A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises -

- How do gene therapies fit into the overall portfolios of these companies?
- What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?

Reasons to buy

This report will allow you to -

- Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.
- Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, infectious diseases, central nervous system disorders, and genetic disorders.
- Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. Understand the level of involvement on the part of big pharma companies, and the extent to which gene therapies fit into the overall portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing multiple gene therapies is provided.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

  • $ 2995
  • Industry report
  • April 2017
  • by Currentpartnering

Summary The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered ...

The 2018-2023 World Outlook for Gene Therapy

The 2018-2023 World Outlook for Gene Therapy

  • $ 995
  • Industry report
  • April 2017
  • by ICON Group

This study covers the world outlook for gene therapy across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the ...

Global Regenerative Medicine Market Analysis & Forecast to 2021; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

Global Regenerative Medicine Market Analysis & Forecast to 2021; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

  • $ 4900
  • Industry report
  • May 2017
  • by Kelly Scientific Publications

This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential ...


Download Unlimited Documents from Trusted Public Sources

Cytokine Industry in the US

  • May 2017
    12 pages
  • Cytokine  

  • United States  

View report >

Tissue Engineering Industry in the UK

  • April 2017
    33 pages
  • Tissue Engineer...  

    Cell Therapy  

    Molecular Biolo...  

  • United Kingdom  

View report >

Biochemical Supply

  • April 2017
    2 pages
  • Biochemical  

    Biopharmaceutic...  

    Bioprocessing  

  • Europe  

    Portugal  

    United Kingdom  

View report >

Related Market Segments :

Gene Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.